This company listing is no longer active
CALT Overzicht aandelen
A commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 6/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor CALT uit onze risicocontroles.
Calliditas Therapeutics AB (publ) Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | SEK 40.00 |
| 52 Week Hoogtepunt | SEK 43.00 |
| 52 Week Laag | SEK 15.25 |
| Bèta | 1.46 |
| 11 maand verandering | -1.16% |
| 3 maanden verandering | 3.00% |
| 1 Jaar Verandering | 115.75% |
| 33 jaar verandering | 81.16% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | 106.19% |
Recent nieuws en updates
Recent updates
Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics
May 28Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
Aug 18Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy
Jul 15Calliditas submits nefecon marketing authorisation application to the EMA
May 28Calliditas shares rise 10% as FDA grants priority review for Nefecon
Apr 28Calliditas Therapeutics reports Q3 results
Nov 12Rendement voor aandeelhouders
| CALT | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -1.8% | 0.3% | 0.3% |
| 1Y | 115.8% | 23.6% | 38.3% |
Rendement versus industrie: CALT exceeded the US Pharmaceuticals industry which returned 21.8% over the past year.
Rendement versus markt: CALT exceeded the US Market which returned 30.2% over the past year.
Prijsvolatiliteit
| CALT volatility | |
|---|---|
| CALT Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: CALT has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: CALT's weekly volatility has decreased from 12% to 2% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2004 | 222 | Renee Aguiar-Lucander | www.calliditas.se |
Calliditas Therapeutics AB (publ) Samenvatting
| CALT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.10b |
| Inkomsten(TTM) | -US$47.15m |
| Inkomsten(TTM) | US$157.19m |
7.0x
P/S-verhouding-23.2x
Koers/WinstverhoudingIs CALT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CALT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | SEK 1.60b |
| Kosten van inkomsten | SEK 104.68m |
| Brutowinst | SEK 1.50b |
| Overige uitgaven | SEK 1.98b |
| Inkomsten | -SEK 480.36m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
Nov 11, 2024
| Winst per aandeel (EPS) | -8.89 |
| Brutomarge | 93.46% |
| Nettowinstmarge | -30.00% |
| Schuld/Eigen Vermogen Verhouding | 920.0% |
Hoe presteerde CALT op de lange termijn?
Bekijk historische prestaties en vergelijking